FR23C1011I1 - Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations - Google Patents

Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations

Info

Publication number
FR23C1011I1
FR23C1011I1 FR23C1011C FR23C1011C FR23C1011I1 FR 23C1011 I1 FR23C1011 I1 FR 23C1011I1 FR 23C1011 C FR23C1011 C FR 23C1011C FR 23C1011 C FR23C1011 C FR 23C1011C FR 23C1011 I1 FR23C1011 I1 FR 23C1011I1
Authority
FR
France
Prior art keywords
bcma
binding
bispecific antigen
antibodies
binding molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR23C1011C
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56740579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR23C1011(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR23C1011I1 publication Critical patent/FR23C1011I1/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR23C1011C 2015-08-17 2023-02-22 Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations Active FR23C1011I1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562206246P 2015-08-17 2015-08-17
PCT/US2016/047146 WO2017031104A1 (en) 2015-08-17 2016-08-16 Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof

Publications (1)

Publication Number Publication Date
FR23C1011I1 true FR23C1011I1 (fr) 2023-04-14

Family

ID=56740579

Family Applications (2)

Application Number Title Priority Date Filing Date
FR23C1011C Active FR23C1011I1 (fr) 2015-08-17 2023-02-22 Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
FR23C1012C Active FR23C1012I2 (fr) 2015-08-17 2023-02-22 Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR23C1012C Active FR23C1012I2 (fr) 2015-08-17 2023-02-22 Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations

Country Status (40)

Country Link
US (1) US10072088B2 (enExample)
EP (3) EP4667058A3 (enExample)
JP (4) JP2018525005A (enExample)
KR (2) KR102890745B1 (enExample)
CN (1) CN108350076B (enExample)
AR (2) AR105724A1 (enExample)
AU (1) AU2016308567B2 (enExample)
CA (1) CA2995754A1 (enExample)
CL (1) CL2018000431A1 (enExample)
CO (1) CO2018001524A2 (enExample)
CY (2) CY1123297T1 (enExample)
DK (1) DK3337824T3 (enExample)
EA (1) EA201890513A1 (enExample)
EC (1) ECSP18019568A (enExample)
ES (1) ES2814550T3 (enExample)
FI (1) FIC20230012I1 (enExample)
FR (2) FR23C1011I1 (enExample)
HR (1) HRP20201375T1 (enExample)
HU (2) HUE050556T2 (enExample)
IL (3) IL298041B2 (enExample)
JO (1) JO3799B1 (enExample)
LT (2) LT3337824T (enExample)
LU (1) LUC00301I2 (enExample)
MA (1) MA53750A (enExample)
MX (2) MX2018002043A (enExample)
MY (1) MY191325A (enExample)
NI (1) NI201800027A (enExample)
NL (1) NL301219I2 (enExample)
PE (1) PE20180795A1 (enExample)
PH (1) PH12018500361A1 (enExample)
PL (1) PL3337824T3 (enExample)
PT (1) PT3337824T (enExample)
RS (1) RS60755B1 (enExample)
SI (1) SI3337824T1 (enExample)
SV (1) SV2018005634A (enExample)
TW (3) TWI811023B (enExample)
UA (1) UA127515C2 (enExample)
UY (2) UY36859A (enExample)
WO (1) WO2017031104A1 (enExample)
ZA (1) ZA201801789B (enExample)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014124280A1 (en) 2013-02-08 2014-08-14 Institute For Myeloma & Bone Cancer Research Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
GB201317928D0 (en) * 2013-10-10 2013-11-27 Ucl Business Plc Molecule
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
EP3297672B1 (en) 2015-05-21 2021-09-01 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
DK3402515T3 (da) 2016-01-12 2021-11-15 Oncotracker Inc Forbedrede fremgangsmåder til monitorering af et individs immunstatus
AR107582A1 (es) 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
MA44254A (fr) 2016-02-17 2018-12-26 Seattle Genetics Inc Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
US10968279B2 (en) * 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
KR102530742B1 (ko) 2016-05-20 2023-05-09 하푼 테라퓨틱스, 인크. 단일 도메인 혈청 알부민 결합 단백질
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
CR20220578A (es) 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
WO2018124766A2 (ko) 2016-12-28 2018-07-05 주식회사 녹십자랩셀 키메라 항원 수용체 및 이를 발현하는 자연 살해 세포
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
SG10202107880XA (en) 2017-05-12 2021-09-29 Harpoon Therapeutics Inc Mesothelin binding proteins
US11635435B2 (en) 2017-06-13 2023-04-25 Oncotracker, Inc. Diagnostic, prognostic, and monitoring methods for solid tumor cancers
CN110891971B (zh) * 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
JP7240335B2 (ja) * 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
UA126813C2 (uk) * 2017-08-01 2023-02-08 Медімм'Юн, Ллк Моноклональний кон’югат антитіло-лікарський засіб до bcma
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CA3070468A1 (en) * 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
CA3078969A1 (en) * 2017-10-13 2019-04-18 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
US11066475B2 (en) 2017-11-01 2021-07-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides
MA49911A (fr) * 2017-11-01 2020-06-24 Juno Therapeutics Inc Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
WO2019099639A1 (en) 2017-11-15 2019-05-23 Navartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
WO2019136432A1 (en) 2018-01-08 2019-07-11 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019190969A1 (en) * 2018-03-26 2019-10-03 Sutro Biopharma, Inc. Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
EP3774914A2 (en) * 2018-04-13 2021-02-17 Affimed GmbH Nk cell engaging antibody fusion constructs
MX2020012217A (es) 2018-05-14 2021-03-02 Harpoon Therapeutics Inc Porción de unión para activación condicional de moléculas de inmunoglobulina.
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
PE20210320A1 (es) * 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
IL279367B2 (en) 2018-06-13 2026-05-01 Novartis Ag BCMA chimeric antigen receptors and their uses
US12247084B2 (en) 2018-06-14 2025-03-11 2Seventy Bio, Inc. Anti-BCMA CAR antibodies, conjugates, and methods of use
WO2020004937A1 (ko) 2018-06-26 2020-01-02 주식회사 티에스디라이프사이언스 항-bcma 항체-약물 접합체 및 그 용도
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
LT4324851T (lt) 2018-07-19 2025-10-10 Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
MX2021001083A (es) * 2018-07-31 2021-03-31 Amgen Res Munich Gmbh Regimen posologico para anticuerpos biespecificos contra bcma-cd3.
CA3108427A1 (en) * 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
SI3844267T1 (sl) 2018-08-31 2025-10-30 Novartis Ag Postopki izdelave celic, ki izražajo receptorje himernega antigena
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
US12116415B2 (en) 2018-10-09 2024-10-15 Single Cell Technology, Inc. Anti-BCMA antibodies
US12473345B2 (en) 2018-11-01 2025-11-18 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
BR112021008486A2 (pt) * 2018-11-01 2021-10-26 Shandong New Time Pharmaceutical Co., Ltd Anticorpo biespecífico e seu uso
JP2022515152A (ja) * 2018-12-19 2022-02-17 シティ・オブ・ホープ Ｂａｆｆ－ｒ二重特異性ｔ細胞エンゲージャー抗体
CN113795512A (zh) * 2019-02-01 2021-12-14 葛兰素史克知识产权开发有限公司 包含贝兰他单抗莫福汀和抗ox4抗体的癌症组合治疗及其用途和方法
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
US20220152150A1 (en) 2019-02-25 2022-05-19 Novartis Ag Mesoporous silica particles compositions for viral delivery
KR20210133261A (ko) * 2019-02-26 2021-11-05 소렌토 쎄라퓨틱스, 인코포레이티드 Bcma에 결합하는 항원 결합 단백질
EP3941938A1 (en) 2019-03-06 2022-01-26 Dana-Farber Cancer Institute, Inc. T cell receptors specific to b-cell maturation antigen for treatment of cancer
KR20210143246A (ko) 2019-03-21 2021-11-26 리제너론 파아마슈티컬스, 인크. 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용
EP3942025A1 (en) 2019-03-21 2022-01-26 Novartis AG Car-t cell therapies with enhanced efficacy
CA3133654A1 (en) 2019-04-05 2020-10-08 Teneobio, Inc. Heavy chain antibodies binding to psma
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020219742A1 (en) 2019-04-24 2020-10-29 Novartis Ag Compositions and methods for selective protein degradation
EP3733707A1 (en) 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
CN113966344A (zh) * 2019-05-03 2022-01-21 细胞基因公司 抗-bcma抗体结合物、包含其的组合物及其制备及使用方法
WO2020232303A1 (en) 2019-05-14 2020-11-19 Harpoon Therapeutics, Inc. EpCAM BINDING PROTEINS AND METHODS OF USE
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
CN114206927B (zh) 2019-06-14 2025-03-21 特尼奥生物股份有限公司 与cd22和cd3结合的多特异性重链抗体
CN111269315B (zh) 2019-06-19 2022-04-08 北京智仁美博生物科技有限公司 针对bcma的单克隆抗体
US12703758B2 (en) 2019-06-19 2026-08-11 Changqing Genrix Biopharmaceutical Co., Ltd. Anti-CD3E/BCMA bispecific antibody and use thereof
BR112022001546A2 (pt) * 2019-07-30 2022-03-22 Jiangsu Hansoh Pharmaceutical Group Co Ltd Anticorpo anti-bcma, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment
HUE068401T2 (hu) 2019-11-11 2024-12-28 Amgen Res Munich Gmbh A BCMA elleni hatóanyagok adagolási rendje
WO2021108661A2 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
JP7693672B2 (ja) * 2019-12-06 2025-06-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 二重特異性抗ｂｃｍａ×抗ｃｄ３抗体により多発性骨髄腫を治療する方法
WO2021113776A1 (en) 2019-12-06 2021-06-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to bcma-targeted binding domains and related compositions and methods
CN114829405B (zh) * 2019-12-10 2025-07-18 爱必乐生物公司 抗bcma/抗4-1bb双特异性抗体及其用途
WO2021132746A1 (en) * 2019-12-24 2021-07-01 Abl Bio, Inc. Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
EP4076522A4 (en) * 2019-12-16 2024-04-10 2seventy bio, Inc. Anti-bcma car antibodies, conjugates, and methods of use
WO2021138474A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
JP7456075B2 (ja) * 2020-01-03 2024-03-27 ビオシオン インコーポレイテッド 抗体結合ｂｃｍａ及びその使用
JP2023516008A (ja) 2020-02-27 2023-04-17 ノバルティス アーゲー キメラ抗原受容体発現細胞を作製する方法
IL295878A (en) 2020-02-27 2022-10-01 Novartis Ag Methods for producing cells expressing a chimeric antigen receptor
WO2021183845A1 (en) * 2020-03-13 2021-09-16 Janssen Biotech, Inc. Materials and methods for modulating delta chain mediated immunity
TW202144425A (zh) * 2020-04-17 2021-12-01 大陸商上海翰森生物醫藥科技有限公司 特異性抗原結合分子，其製備方法及醫藥用途
KR20250007022A (ko) * 2020-04-29 2025-01-13 테네오원, 인코포레이티드 변형된 중쇄 불변 영역을 갖는 다중특이적 중쇄 항체
CN113637073B (zh) 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
TW202207977A (zh) 2020-05-19 2022-03-01 美商健生生物科技公司 包含ｔ細胞重導向治療劑及ｖｌａ－４黏附路徑抑制劑之組成物
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
IL299027A (en) 2020-06-30 2023-02-01 Teneobio Inc Multispecific antibodies that bind BCMA
EP4545569A3 (en) * 2020-06-30 2025-10-08 Harbour Biomed (Shanghai) Co., Ltd Binding protein having h2l2 and hcab structures
CN114075287B (zh) 2020-08-18 2023-07-21 湖南远泰生物技术有限公司 人源化bcma抗体和bcma-car-t细胞
WO2022040586A2 (en) 2020-08-21 2022-02-24 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
CN116615456A (zh) * 2020-09-11 2023-08-18 詹森生物科技公司 用于调节β链介导的免疫的方法和组合物
KR20230069181A (ko) * 2020-09-14 2023-05-18 화이자 인코포레이티드 암 치료를 위한 방법, 요법 및 용도
AU2021345124A1 (en) 2020-09-16 2023-03-30 Amgen Inc. Methods for administering therapeutic doses of bispecific T-cell engaging molecules for the treatment of cancer
TWI917473B (zh) 2020-11-02 2026-03-11 新加坡商蜂鳥生物科技私人有限公司 Bcma/taci抗原結合分子
WO2022098771A1 (en) * 2020-11-03 2022-05-12 Ab Studio Inc. Multispecific antibodies and uses thereof
JP2023549780A (ja) 2020-11-04 2023-11-29 ジュノー セラピューティクス インコーポレイテッド 改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
CN118878693A (zh) * 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
CN114573703A (zh) * 2020-12-02 2022-06-03 康诺亚生物医药科技（成都）有限公司 一种t细胞衔接器治疗剂的开发和应用
WO2022135468A1 (zh) * 2020-12-23 2022-06-30 信达生物制药(苏州)有限公司 抗bcma×cd3双特异性抗体及其用途
CA3202891A1 (en) 2021-01-28 2022-08-04 Kara Olson Compositions and methods for treating cytokine release syndrome
WO2022175255A2 (en) 2021-02-16 2022-08-25 Janssen Pharmaceutica Nv Trispecific antibody targeting bcma, gprc5d, and cd3
EP4301785A4 (en) * 2021-03-05 2025-04-23 Atreca, Inc. ANTI-EPHA2 ANTIBODIES
CA3214594A1 (en) 2021-03-24 2022-09-29 Janssen Biotech, Inc. Trispecific antibody targeting cd79b, cd20, and cd3
CA3214757A1 (en) 2021-04-08 2022-10-13 Andreas Loew Multifuntional molecules binding to tcr and uses thereof
KR20230170721A (ko) * 2021-04-15 2023-12-19 치아타이 티안큉 파마수티컬 그룹 주식회사 Bcma를 표적으로 하는 다중 특이성 항체
AR125468A1 (es) 2021-04-27 2023-07-19 Novartis Ag Sistema de producción de vectores virales
CN117396231A (zh) 2021-04-30 2024-01-12 新基公司 使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
KR20240014482A (ko) 2021-05-28 2024-02-01 얀센 바이오테크 인코포레이티드 B 세포 림프종에서 T 세포 재지향 항체에 대한 표적으로서의 Bcma
CN115521381B (zh) * 2021-06-24 2024-10-29 益科思特(北京)医药科技发展有限公司 结合bcma和cd3的双特异性抗体及其制备方法与应用
CN115569191A (zh) * 2021-07-05 2023-01-06 山东新时代药业有限公司 一种重组人源化抗bcma/cd3双特异性抗体冻干制剂
WO2023020474A1 (en) * 2021-08-16 2023-02-23 Utc Therapeutics (Shanghai) Co., Ltd. Bcma targetting antibodies and uses thereof in cancer therapies
EP4388000A1 (en) 2021-08-20 2024-06-26 Novartis AG Methods of making chimeric antigen receptor?expressing cells
MX2024003887A (es) 2021-10-14 2024-07-09 Arsenal Biosciences Inc Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica.
CN118159563A (zh) * 2021-10-27 2024-06-07 詹森生物科技公司 用于人和猴组织中的增强型bcma免疫组织化学检测的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES
US20230134748A1 (en) 2021-11-03 2023-05-04 Janssen Biotech, Inc. Corticosteriod Reduction in Treatment with Anti-CD38 Antibody
WO2023086817A1 (en) * 2021-11-10 2023-05-19 Janssen Biotech, Inc. Stable formulations comprising a bispecific bcma/cd3 antibody
EP4428156A4 (en) * 2021-12-03 2026-03-04 Shandong Simcere Biopharmaceutical Co., Ltd. ANTI-BCMA NANOBODY AND USE THEREOF
AU2023254191A1 (en) 2022-04-11 2024-10-17 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
CN117003871A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合bcma和cd3的抗体及其用途
CN116023504B (zh) * 2022-06-07 2025-09-30 江苏蒙彼利生物科技有限公司 双特异性嵌合抗原受体（car）及其制备方法
JP2026519263A (ja) 2022-10-26 2026-06-15 ノバルティス アーゲー レンチウイルス製剤
IL320562A (en) 2022-11-02 2025-07-01 Janssen Biotech Inc Cancer treatment methods
WO2024102954A1 (en) 2022-11-10 2024-05-16 Massachusetts Institute Of Technology Activation induced clipping system (aics)
WO2024119126A1 (en) * 2022-12-02 2024-06-06 Artiva Biotherapeutics, Inc. Anti-bcma antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
CN117186229B (zh) * 2022-12-06 2024-03-29 成都赛恩吉诺生物科技有限公司 具有长cdr3序列的抗人bcma纳米抗体及car-t和应用
WO2024124088A1 (en) * 2022-12-09 2024-06-13 Sana Biotechnology, Inc. Bcma-specific antibody constructs and compositions thereof
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體
IL323990A (en) * 2023-04-19 2025-12-01 Janssen Biotech Inc Methods for treating multiple myeloma
CN121358776A (zh) 2023-05-09 2026-01-16 詹森生物科技公司 包含高浓度的双特异性bcma/cd3抗体的药物组合物
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
EP4725970A1 (en) 2023-06-06 2026-04-15 Fortvita Biologics Inc. Preparation and use of anti-gprc5d/bcma/cd3 trispecific antibody
CN121969385A (zh) 2023-09-11 2026-05-01 丹娜-法伯癌症研究院 含有il-2变体以增强car t细胞的功能性的car-衔接子
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
AU2024370890A1 (en) 2023-10-30 2026-06-11 Leads Biolabs Inc. Antibody binding to bcma and multispecific antibody comprising same
IL328139A (en) 2023-11-01 2026-06-01 Janssen Biotech Inc Methods for treating multiple myeloma
WO2025094107A1 (en) 2023-11-01 2025-05-08 Janssen Biotech, Inc. Methods for treating high-risk smoldering multiple myeloma
WO2025131077A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3多特异性抗体及用途
CN122295373A (zh) 2023-12-28 2026-06-26 南通壹宸生物医药科技有限公司 融合抗体及其应用
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025243241A1 (en) 2024-05-23 2025-11-27 Janssen Biotech, Inc. Methods for treating multiple myeloma
WO2026033437A1 (en) 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies
WO2026124586A1 (zh) * 2024-12-12 2026-06-18 华夏英泰（北京）医药科技有限公司 靶向bcma的抗体及其应用
WO2026151982A1 (en) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Methods of treating food allergy by administering an il-4r antagonist and a bcma targeting agent

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2243007T3 (es) 1997-09-16 2005-11-16 Egea Biosciences Llc Sintesis quimica completa y sintesis de genes de genomas.
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
US20020142000A1 (en) 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
US8236308B2 (en) 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008119565A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific binding domain
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
PL2155788T3 (pl) 2007-04-03 2013-02-28 Amgen Res Munich Gmbh Swoiste międzygatunkowe bispecyficzne czynniki wiążące
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
AU2009299794B2 (en) 2008-10-01 2015-08-13 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
EP2352763B2 (en) 2008-10-01 2022-09-21 Amgen Research (Munich) GmbH Bispecific single chain antibodies with specificity for high molecular weight target antigens
MX2011003502A (es) 2008-10-01 2011-09-01 Micromet Ag Anticuerpo de cadena sencilla biespecifica de psmaxcd3 especifico a traves de especies.
MX2011004550A (es) 2008-10-31 2011-07-20 Centocor Ortho Biotech Inc Composiciones de de supercóntigos a base de dominios de fibronectina tipo iii, métodos y usos.
CN102596992B (zh) 2009-02-12 2015-09-09 詹森生物科技公司 基于ⅲ型纤连蛋白结构域的支架组合物、方法及用途
CN102421801B (zh) 2009-03-10 2016-03-16 比奥根Ma公司 抗-bcma抗体
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
CA2880791A1 (en) * 2011-08-03 2013-02-07 Children's Medical Center Corporation A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin
US9574010B2 (en) 2011-11-04 2017-02-21 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the Fc domain
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2014093908A2 (en) 2012-12-14 2014-06-19 Omt, Inc. Polynucleotides encoding rodent antibodies with human idiotypes and animals comprising same
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
EP2762497A1 (en) * 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途

Also Published As

Publication number Publication date
AU2016308567A1 (en) 2018-03-08
KR20250007058A (ko) 2025-01-13
CL2018000431A1 (es) 2018-11-23
UY36859A (es) 2017-04-28
NL301219I2 (nl) 2023-04-04
CY1123297T1 (el) 2021-12-31
ZA201801789B (en) 2019-10-30
CA2995754A1 (en) 2017-02-23
NZ739862A (en) 2025-05-02
IL257468B2 (en) 2023-06-01
EP3337824A1 (en) 2018-06-27
LUC00301I2 (enExample) 2025-09-22
JP2021184721A (ja) 2021-12-09
PH12018500361A1 (en) 2018-09-03
JP2018525005A (ja) 2018-09-06
HUE050556T2 (hu) 2020-12-28
DK3337824T3 (da) 2020-08-24
CY2023007I2 (el) 2023-11-15
EP4667058A2 (en) 2025-12-24
US10072088B2 (en) 2018-09-11
FR23C1012I1 (fr) 2023-04-14
TWI777924B (zh) 2022-09-21
MX2022006650A (es) 2022-07-05
PE20180795A1 (es) 2018-05-09
IL298041B1 (en) 2025-06-01
AR105724A1 (es) 2017-11-01
JO3799B1 (ar) 2021-01-31
PL3337824T3 (pl) 2021-04-19
AR134557A2 (es) 2026-01-28
JP7194240B2 (ja) 2022-12-21
TWI811023B (zh) 2023-08-01
CY2023007I1 (el) 2023-06-09
AU2016308567B2 (en) 2022-10-27
RS60755B1 (sr) 2020-10-30
IL257468A (en) 2018-04-30
SV2018005634A (es) 2018-06-26
MX2018002043A (es) 2018-07-06
PT3337824T (pt) 2020-09-10
JP2025013894A (ja) 2025-01-28
KR102890745B1 (ko) 2025-11-26
EP3337824B1 (en) 2020-06-03
BR112018003017A2 (pt) 2018-09-25
CO2018001524A2 (es) 2018-07-10
MY191325A (en) 2022-06-15
ECSP18019568A (es) 2018-04-30
IL298041A (en) 2023-01-01
CN108350076A (zh) 2018-07-31
KR20180040671A (ko) 2018-04-20
HUS2300011I1 (hu) 2023-03-28
LT3337824T (lt) 2020-09-25
LTC3337824I2 (enExample) 2024-10-25
FR23C1012I2 (fr) 2025-01-10
MA53750A (fr) 2021-09-15
WO2017031104A1 (en) 2017-02-23
CN108350076B (zh) 2022-06-07
ES2814550T3 (es) 2021-03-29
JP7621324B2 (ja) 2025-01-24
UY40513A (es) 2023-11-30
TW201718651A (zh) 2017-06-01
EA201890513A1 (ru) 2018-11-30
NL301219I1 (enExample) 2023-03-01
EP3757131A1 (en) 2020-12-30
LTPA2023509I1 (enExample) 2023-03-10
US20170051068A1 (en) 2017-02-23
TW202406935A (zh) 2024-02-16
SI3337824T1 (sl) 2020-10-30
IL298041B2 (en) 2025-10-01
TW202307000A (zh) 2023-02-16
JP2023027228A (ja) 2023-03-01
FIC20230012I1 (fi) 2023-02-22
IL320478A (en) 2025-06-01
NI201800027A (es) 2018-08-30
EP4667058A3 (en) 2026-04-01
HRP20201375T1 (hr) 2020-11-27
UA127515C2 (uk) 2023-09-20

Similar Documents

Publication Publication Date Title
FR23C1012I1 (fr) Anticorps anti-bcma, molécules bispécifiques de liaison à un antigène liant bcma et cd3 et leurs utilisations
MA43164A (fr) Anticorps anti-il1rap, molécules bispécifiques de liaison à un antigène liant il1rap et cd3 et leurs utilisations
FR26C1002I1 (fr) Anticorps anti-gprc5d, molécules bispécifiques de liaison à l'antigène qui se lient à gprc5d et cd3 et leurs utilisations
MA44060A (fr) Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations
DK3411402T3 (da) Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner
HRP20260436T1 (hr) Bispecifično protutijelo koje veže dll3 i cd3
EP3356416A4 (en) PD-1 ANTIBODIES AND USES THEREOF
MA42935A (fr) Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
EP3452089A4 (en) BISPECIFIC BINDING PROTEINS AND THEIR USE
EP3328895A4 (en) ANTI-PD-1 ANTIBODIES AND USES THEREOF
EP3370769A4 (en) SPECIFIC TO TIM-3 BINDING ANTIBODIES AND THEIR USE
MA46917A (fr) Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation
EP3389699A4 (en) CHIMERIC AND HUMANIZED MONOCLONAL ANTIBODIES TO HUMAN CTLA4 AND USES THEREOF
MA43308A (fr) Molécules d'anticorps se liant à april et leurs utilisations
EA202092435A2 (ru) Моноклональные антитела против bcma
EP3377102A4 (en) ANTI-PD-1 ANTIBODIES AND THEIR THERAPEUTIC USES
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3426686A4 (en) HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
HUE061419T2 (hu) ANTI-PSMA antitestek, PSMA-t és CD3-at megkötõ bispecifikus antigénkötõ molekulák és azok alkalmazása
HUE054384T2 (hu) EGFRVIII-T és CD3-at kötõ bispecifikus antitest-konstrukciók
MA42059A (fr) Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
EP3283517A4 (en) ANTI-PACAP ANTIBODIES AND USES THEREOF
MA42821A (fr) Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
EP3661555A4 (en) SPECIFIC ANTIBODIES AND USES THEREOF